Science and Engineering Ethics

, Volume 8, Issue 3, pp 443–454 | Cite as

Academic-industrial relationships: Opportunities and pitfalls

  • Joseph B. MartinEmail author
  • Thomas P. Reynolds


Over the past 50 years, academic-industrial collaborations and technology transfer have played an increasingly prominent role in the biomedical sciences. These relationships can speed the delivery of innovative drugs and medical technologies to clinical practice, creating important public health benefits as well as income for universities and their faculty. At the same time, they raise ethical concerns, particularly when research involves human subjects in clinical trials. Lapses in oversight of industry sponsored clinical trials at universities, and especially patient deaths in a number of trials, have brought these issues into the public spotlight and have led the federal government to intensify its oversight of clinical research. The leadership of Harvard Medical School convened a group of leaders in academic medicine to formulate guidelines on individual financial conflicts of interest. They and other groups are working to formulate a national consensus on this issue.


Mutual Fund Harvard Medical School Engineer Ethic Academic Medicine Financial Interest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Angell, M. (2000) Is academic medicine for sale? N Engl J Med 342(20): 1516–8.CrossRefGoogle Scholar
  2. 2.
    Weatherall, D. (2000) Academia and industry: increasingly uneasy bedfellows, Lancet 355(9215): 1574.CrossRefGoogle Scholar
  3. 3.
    Cho, M.K., Shohara, R., et al. (2000) Policies on faculty conflicts of interest at US universities, JAMA 284(17): 2203–8.CrossRefGoogle Scholar
  4. 4.
    Boyd, E.A. and Bero, L.A. (2000) Assessing faculty financial relationships with industry. A case study, JAMA 284(17): 2209–14.CrossRefGoogle Scholar
  5. 5.
    Lo, B., Wolf, L.E., et al. (2000) Conflict-of-interest policies for investigators in clinical trials, N Engl J Med 343(22): 1616–20.CrossRefGoogle Scholar
  6. 6.
    Martin, J.B. and Kasper, D.L. (2000) In whose best interest? Breaching the academic-industrial wall, N Engl J Med 343(22): 1646–9.CrossRefGoogle Scholar
  7. 7.
    Protecting Subjects, Preserving Trust, Promoting Progress: Policy and Guidelines for the Oversight of Individual Financial Interests in Human Subjects Research (2001) Association of American Medical Colleges, Washington, D.C.Google Scholar
  8. 8.
    Moses, H.3rd and Martin, J.B. (2001) Academic relationships with industry: a new model for biomedical research, JAMA 285(7): 933–5.CrossRefGoogle Scholar

Copyright information

© Opragen Publications 2002

Authors and Affiliations

  1. 1.Harvard Medical SchoolBostonUSA

Personalised recommendations